By Kim Han-joo
SEOUL, July 1 (Yonhap) -- South Korean drugmaker Yuhan Corp. said Monday that it has signed a US$870 million deal with German biotechnology firm Boehringer Ingelheim to export its new liver disease treatment technology.
The deal calls for the two companies to enter into a collaboration agreement to co-develop novel therapeutic candidates for the treatment of patients with advanced fibrosis due to nonalcoholic steatohepatitis (NASH), officials said.
The deal includes an upfront payment of $40 million, and Yuhan will receive another $830 million in potential milestone payments upon achievement of certain developments, officials said.
The technologies are related to a novel convergence protein called "GLP-1 and FGF21 dual agonist" that is known to lower nonalcoholic fatty liver disease activity.
NASH is a chronic and progressive liver disease characterized by fat accumulation of more than 5 percent and inflammation in the liver. The disease, which currently has limited treatment, can lead to fibrosis that affects liver function.
S. Korea's space program opens new chapter with rocket engine launch, satellites
Samsung aims to overcome biz hurdles through 180 tln won investment
Naver's relinquishing of news editing first step to addressing opinion rigging concerns
(News Focus) All eyes on Samsung's stock split, impact on share value
Samsung's stock split move to make it possible for ordinary investors to buy-sell shares